SUPN
Supernus Pharmaceuticals Inc
43.80$
+2.3%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 79.2% | 56.2% | 48.9% | 53.8% | 50.5% | 40.7% | 41.9% | 35.6% | 43.1% | 38.6% | 50.1% | 44.3% | |
| 54.1% | 33.0% | 29.1% | 23.6% | 19.7% | 15.6% | 19.2% | 12.0% | 5.5% | 5.9% | 5.1% | 8.8% | |
| 54.1% | 33.0% | 29.1% | 33.0% | 36.4% | 29.9% | 28.1% | 20.1% | 27.1% | 19.9% | 33.2% | 21.2% | |
| 12.6% | 13.7% | 13.4% | 15.5% | 10.5% | 7.5% | 9.4% | 8.8% | 9.7% | 11.3% | 10.4% | 12.9% | |
| 9.8% | 6.7% | 5.4% | 3.8% | 2.6% | 2.3% | 3.2% | 5.1% | 5.4% | 6.1% | 4.0% | 5.7% | |
| 1.8% | 2.1% | 1.4% | 1.2% | 0.4% | 1.5% | 2.5% | 3.1% | 2.6% | – | – | – | |
| 4.0% | 0.5% | 5.3% | 8.5% | 3.2% | 2.1% | 5.2% | 7.0% | 6.9% | 9.2% | 8.6% | 8.6% | |
| 4.0% | 0.5% | 5.3% | 8.5% | 3.2% | 2.1% | 24.2% | 46.5% | 41.3% | 47.0% | 38.1% | 39.2% | |
| 48.1% | 37.0% | 38.1% | 37.0% | 53.7% | 48.7% | 50.5% | 51.7% | 47.9% | 27.9% | 24.3% | 26.9% | |
| 20.0% | 29.7% | 26.1% | 29.0% | 16.5% | 13.8% | 16.3% | 18.7% | 40.4% | 22.7% | 21.4% | 23.3% | |
| 19.1% | 0.3% | 22.4% | 1.0% | 0.2% | 0.2% | 0.2% | 0.4% | 24.0% | 0.7% | 0.5% | 0.7% | |
| 1.4% | 2.3% | 2.6% | 1.6% | 0.3% | 0.9% | 0.4% | 0.6% | 0.6% | 0.2% | 0.3% | 0.2% | |
| 19.6% | 3.8% | 1.3% | 0.0% | 33.7% | 29.7% | 24.1% | 22.5% | – | – | – | – | |
| 51.9% | 63.0% | 61.9% | 63.0% | 46.3% | 51.3% | 49.5% | 48.3% | 52.1% | 72.1% | 75.7% | 73.1% | |
| -115.4% | -76.6% | -27.2% | -6.3% | 8.8% | 17.2% | 21.7% | 22.5% | 28.3% | 37.8% | 40.7% | 35.7% | |
| 36.8% | 27.1% | 16.7% | 12.6% | 5.5% | 4.6% | 3.6% | 3.2% | 3.6% | 4.3% | 4.1% | 3.9% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.